Consumer Packaged Goods, Food & Household Brands · vs · Pharmaceuticals, Biotech & Life Sciences Brands
Celsius vs Johnson & Johnson
Structured technology and market comparison · 2026
Direct Feature Comparison
Celsius · vs · Johnson & Johnson| Attribute | ||
|---|---|---|
| Market Cluster / Sector | Consumer Packaged Goods, Food & Household Brands | Pharmaceuticals, Biotech & Life Sciences Brands |
| Business Model / Role | Advertiser / Brand | Advertiser / Brand |
| Platform Focus | Large US company named Celsius with insufficient product detail. | Large public healthcare manufacturer and commercial products company. |
| Company Size | 1,001–5,000 employees | >5,000 employees |
| Headquarters | United States | United States |
| Year Founded | 2004 | 1887 |
| Dossier & Alternatives |
Analyze all overlapping signals and tech stacks for Celsius and Johnson & Johnson
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Celsius and Johnson & Johnson?
When comparing Celsius and Johnson & Johnson, both platforms operate within the Advertiser / Brand ecosystem. Celsius is positioned as Large US company named Celsius with insufficient product detail, whereas Johnson & Johnson focuses on Large public healthcare manufacturer and commercial products company. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Celsius and Johnson & Johnson?
When evaluating Celsius and Johnson & Johnson, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Celsius and Johnson & Johnson compare?
Celsius is headquartered in United States (founded in 2004) with 1,001–5,000 employees. Johnson & Johnson is based in United States (founded in 1887) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Celsius vs Johnson & Johnson
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Celsius
Recent Signals
- ·Modern RetailSports Marketing
Celsius Expands Sports Marketing in 2026
Energy drink brand Celsius is aggressively expanding its sports marketing efforts in 2026, leveraging partnerships with major sports leagues, college athletics, and high-profile events. The company has become the official energy drink sponsor of ESPN's College GameDay, signed British F1 driver Jessica Hawkins ahead of the Las Vegas Grand Prix, sponsored marathons and fitness events like the ATHX Games, and partnered with Diplo's Run Club. CMO Kyle Watson highlighted the multi-year partnership with Aston Martin Aramco and the umbrella 'Live. Fit. Go.' campaign. The strategy aims to position Celsius as a better-for-you functional beverage for athletes and fitness enthusiasts. By embedding in sports culture, Celsius seeks to deepen consumer connections, leveraging the high emotional engagement of sporting events to enhance brand affinity.
- Celsius signed a multi-year deal to become the official energy drink sponsor of ESPN's College GameDay.
- Celsius signed British F1 driver Jessica Hawkins ahead of the 2026 Las Vegas Grand Prix.
- Celsius sponsored the Club Celsius pop-up at the New York City Marathon and Diplo's Run Club stops.
- ·SEC APIM&A & Corporate Finance
Celsius Reports Q3 2026 Revenue of $847.2M and Strong Profit Rebound
Celsius Holdings, Inc. reported consolidated revenue of $847.2 million for the third quarter of 2026, an increase of 16.8% compared to $725.1 million in Q3 2025. Operating income rebounded to $172.1 million from an operating loss of $80.0 million in the prior-year period, primarily driven by a sharp reduction in distributor termination fees from $246.7 million to $3.5 million following the transition of Alani Nu distribution territory rights to PepsiCo. Net income attributable to common stockholders reached $99.5 million, up from a net loss of $70.7 million in Q3 2025. Brand performance was led by Alani Nu, which delivered revenue of $410.1 million (up 23.5% year-over-year), surpassing the flagship Celsius brand ($356.8 million, down 6.3% due to SKU optimization and distributor inventory rebalancing). Rockstar Energy generated $80.3 million in revenue. During the quarter, Celsius settled its long-running Strong Arm Productions litigation for $85.0 million ($60.0 million paid in September 2026) and executed a second debt refinancing reducing Term Loan interest margins.
- Q3 2026 revenue increased 16.8% year-over-year to $847.2 million, driven by Alani Nu ($410.1 million) and Rockstar ($80.3 million).
- Operating income swung to $172.1 million from an operating loss of $80.0 million in Q3 2025 as distributor termination expenses dropped from $246.7 million to $3.5 million.
- Litigation with Strong Arm Productions (Flo Rida) was settled for $85.0 million, with $60.0 million paid in September 2026 and $25.0 million due in January 2027.
- ·Modern RetailMarketing
Brands Flock to NYC Marathon's 50th with Pop-ups
The 2026 New York City Marathon, celebrating its 50th anniversary, is drawing a diverse range of brands beyond traditional running footwear. Maybelline serves as the race's first official beauty sponsor, hosting activations like a shakeout run with Rendezvous Sports. Energy drink Celsius opens Club Celsius in Brooklyn along the route, featuring group runs, sampling, and recovery sessions. Mattress brand Saatva hosts its first marathon pop-up, including a wellness panel with Tatyana McFadden, leveraging its role as official mattress partner of USA Track & Field. Activewear brand Vuori also debuts its first marathon activation with events at its Flatiron store and a Williamsburg pop-up. These brands tap into the growing running culture and event's emphasis on wellness and community.
- NYC Marathon marks its 50th anniversary and is expected to break participant records.
- Maybelline is the first-ever official beauty sponsor, hosting pre-race events including a shakeout run.
- Celsius opens Club Celsius in Brooklyn from Oct. 30 to Nov. 2 with group runs and sampling.
Johnson & Johnson
Recent Signals
- ·SEC APIfinancials
Johnson & Johnson Furnishes Q3 2026 Earnings Announcement via Current Report
Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.
- Worldwide sales reached $25.40 billion in Q3 2026 (+5.9% YoY) and $74.77 billion for the first nine months (+7.4% YoY), supported by gains in DARZALEX ($4.24 billion in Q3) and TREMFYA ($2.40 billion in Q3).
- Net earnings plummeted to $210 million in Q3 2026 due to a $5.5 billion litigation charge to resolve ovarian talc claims and a $1.0 billion acquired IPR&D charge for Firefly Bio, Inc.
- Total present value of reserves for talc-related legal matters reached approximately $9.0 billion as of September 27, 2026, while the planned separation of the Orthopaedics business remains on track for mid-2027.
- ·Johnson & JohnsonProduct & Platform Launch
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.
- ·Johnson & JohnsonProduct & Platform Launch
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Johnson & Johnson published a behind-the-scenes feature on September 25, 2026, highlighting how the company manufactures and delivers CAR-T cell therapy for multiple myeloma. The article focuses on the complexity of producing and distributing this personalized cancer treatment. No specific clinical data, product names, or commercial terms are disclosed in the provided text.
- Johnson & Johnson published a behind-the-scenes feature on September 25, 2026.
- The article focuses on Johnson & Johnson's CAR-T cell therapy manufacturing and delivery for multiple myeloma.
- The provided article text does not reveal specific product names, trial results, or financial terms.
Start with a company or market. Track what changes.
Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.
Celsius vs. Johnson & Johnson
Compare capabilities, ecosystem relationships, and recent signals side by side in Polaris7.
Company Comparisons
Compare capabilities, ecosystem relationships, and recent signals side by side in Polaris7.
